Closeout of the HALT-PKD trials
Charity G. Moore(University of Pittsburgh Medical Center), Marie C. Hogan(Mayo Clinic), Gertrude Simon(Tufts Medical Center), Godela Brosnahan(University of Colorado Denver), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Susan Spillane(University of Pittsburgh), Barbara Maxwell(Beth Israel Deaconess Medical Center), Frederic F. Rahbari-Oskoui(Emory University), Dana C. Miskulin(Tufts University), Vicente E. Torres(Mayo Clinic in Arizona), Michael F. Flessner, Ronald D. Perrone(Tufts Medical Center), Theodore I. Steinman(Beth Israel Deaconess Medical Center), William E. Braun(Cleveland Clinic), Robert W. Schrier(University of Denver), K.T. Bae(University of Pittsburgh), Peter C. Harris(Mayo Clinic), Arlene B. Chapman(Emory University), Kaleab Z. Abebe(University of Pittsburgh)
Cited by 1
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
|New England Journal of Medicine|2006|1.2k
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Temporal relationships between hormonal and hemodynamic changes in early human pregnancy
|Kidney International|1998|535